Cerulein-induced acute pancreatitis in the rat is significantly ameliorated by treatment with MEK1/2 inhibitors U0126 and PD98059

Pancreas

Volumn 25, Issue 3, 2002, Pages 251-259

  Clemons, Antoinette P ^a   Holstein, Deborah M ^a   Galli, Aurelio ^a   Saunders, Christine ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AMYLASE; CERULETIDE; ENZYME INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; VINBLASTINE;

ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HISTOLOGY; HOMOGENATE; INFLAMMATION; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTECTION; RAT;

ACUTE DISEASE; ANIMALS; BUTADIENES; CAERULEIN; ENZYME INHIBITORS; FLAVONOIDS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; PANCREATITIS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0036786851     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200210000-00007     Document Type: Article

References (34)

1. Bilchik AJ, Leach SD, Zucker KA, et al. Experimental models of acute pancreatitis. J Surg Res 1990;48:639-47.
2. Kitagawa M, Naruse S, Ishiguro H, et al. Pharmaceutical development for treating pancreatic diseases. Pancreas 1998;16:427-31.
3. Zhou W, Levine BA, Olson MS. Lipid mediator production in acute and chronic pancreatitis in the rat. J Surg Res 1994;56:37-44.
4. Zhou W, Shen F, Miller JE, et al. Evidence for altered cellular calcium in the pathogenetic mechanism of acute pancreatitis in rats. J Surg Res 1996;60:147-55.
5. Zhou W, Shen F, Miller JE, et al. Hormonal stimulation of calcium mobilization in the isolated perfused rat pancreas. J Surg Res 1996;60:168-75.
6. Dabrowski A, Groblewski GE, Schafer C, et al. Cholecystokinin and EGF activate a MAPK cascade by different mechanisms in rat pancreatic acinar cells. Am J Physiol 1997;273:C1472-9.
7. Duan RD, Williams JA. Cholecystokinin rapidly activates mitogen-activated protein kinase in rat pancreatic acini. Am J Physiol 1994;267:G401-8.
8. Duan RD, Zheng CF, Guan KL, et al. Activation of MAP kinase kinase (MEK) and Ras by cholecystokinin in rat pancreatic acini. Am J Physiol 1995;268: G1060-5.
9. Bragado MJ, Dabrowski A, Groblewski GE, et al. CCK activates p90rsk in rat pancreatic acini through protein kinase C. Am J Physiol 1997;272:G401-7.
10. Simeone DM, Zhang L, Graziano K, et al. Smad4 mediates activation of mitogenactivated protein kinases by TGF-beta in pancreatic acinar cells. Am J Physiol Cell Physiol 2001;281:C311-9.
11. Dabrowski A, Grady T, Logsdon CD, et al. Jun kinases are rapidly activated by cholecystokinin in rat pancreas both in vitro and in vivo. J Biol Chem 1996;271: 5686-90.
12. Schafer C, Clapp P, Welsh MJ, et al. HSP27 expression regulates CCK-induced changes of the actin cytoskeleton in CHO-CCK-A cells. Am J Physiol 1999;277: C1032-43.
13. Wagner AC, Metzler W, Hofken T, et al. p38 Map kinase is expressed in the pancreas and is immediately activated following cerulein hyperstimulation. Digestion 1999;60:41-7.
14. Charland S, Boucher MJ, Houde M, et al. Somatostatin inhibits Akt phosphorylation and cell cycle entry, but not p42/p44 mitogen-activated protein (MAP) kinase activation in normal and tumoral pancreatic acinar cells. Endocrinology 2001;142:121-8.
15. Grady T, Dabrowski A, Williams JA, et al. Stress-activated protein kinase activation is the earliest direct correlate to the induction of secretagogue-induced pancreatitis in rats. Biochem Biophys Res Commun 1996;227:1-7.
16. Reiners JJ Jr, Lee JY, Clift RE, et al. PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol Pharmacol 1998;53:438-45.
17. Duncia JV, Santella JB 3rd, Higley CA, et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett 1998;8:2839-44.
18. Wagner AC, Mazzucchelli L, Miller M, et al. CEP-1347 inhibits caeruleininduced rat pancreatic JNK activation and ameliorates caerulein pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2000;278:GI65-72.
19. Talarmin H, Rescan C, Cariou S, et al. The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes. Mol Cell Biol 1999;19:6003-11.
20. Choe ES, McGinty JF. N-Methyl-D-aspartate receptors and p38 mitogen-activated protein kinase are required for cAMP-dependent cyclase response element binding protein and Elk-1 phosphorylation in the striatum. Neuroscience 2000;101:607-17.
21. Strohm C, Barancik T, Bruhl ML, et al. Inhibition of the ER-kinase cascade by PD98059 and U0126 counteracts ischemic preconditioning in pig myocardium. J Cardiovasc Pharmacol 2000;36:218-29.
22. Jaffee BD, Manos EJ, Collins RJ, et al. Inhibition of MAP kinase kinase (MEK) results in an anti-inflammatory response in vivo. Biochem Biophys Res Commun 2000;268:647-51.
23. Kuroki Y, Fukushima K, Kanda Y, et al. Neuroprotection by estrogen via extracellular signal-regulated kinase against quinolinic acid-induced cell death in the rat hippocampus. Eur J Neurosci 2001;13:472-6.
24. Zhou W, Levine BA, Olson MS. Platelet-activating factor: a mediator of pancreatic inflammation during cerulein hyperstimulation. Am J Pathol 1993;142: 1504-12.
25. Rosenshein MS, Price TH, Dale DC. Neutropenia, inflammation, and the kinetics of transfused neutrophils in rabbits. J Clin Invest 1979;64:580-5.
26. Lemanske RF Jr, Guthman DA, Oertel H, et al. The biologic activity of mast cell granules. VI. The effect of vinblastine-induced neutropenia on rat cutaneous late phase reactions. J Immunol 1983;130:2837-42.
27. Yoshikawa D, Goto F. Effect of platelet-activating factor antagonist and leukotriene antagonist on endotoxin shock in the rat: role of the leukocyte. Circ Shock 1992;38:29-33.
28. Schramm NL, Limbird LE. Stimulation of mitogen-activated protein kinase by G protein-coupled alpha(2)-adrenergic receptors does not require agonist-elicited endocytosis. J Biol Chem 1999;274:24935-40.
29. Elzi DJ, Bjornsen AJ, MacKenzie T, et al. Ionomycin causes activation of p38 and p42/44 mitogen-activated protein kinases in human neutrophils. Am J Physiol Cell Physiol 2001;281:C350-60.
30. Sandoval D, Gukovskaya A, Reavey P, et al. The role of neutrophils and plateletactivating factor in mediating experimental pancreatitis. Gastroenterology 1996; 111:1081-91.
31. Fujimoto K, Hosotani R, Doi R, et al. Role of neutrophils in cerulein-induced pancreatitis in rats: possible involvement of apoptosis. Digestion 1997;58: 421-30.
32. Kleeff J, Maruyama H, Ishiwata T, et al. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999;116:1202-16.
33. Itakura J, Ishiwata T, Shen B, et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000;85:27-34.
34. Ding X-Z, Tong WG, Adrian TE. 12-Lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylafion and ERK activation. Int J Cancer 2001;94:630-6.